Asciminib is a potent and selective allosteric BCR-ABL1 inhibitor with an IC50 value of 0.5 nM (caliper assay). Moreover, Asciminib is the first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor. In vivo, the combination of ABL001 and Nilotinib (Axon 1396) led to complete disease control and eradicated CML xenograft tumours without recurrence after the cessation of treatment.

KEYWORDS: Asciminib | Supplier | Bcr-Abl inhibitor | ABL001 | ABL-001 | ABL 001 | CAS [1492952-76-7] | [2119669-71-3] | [2679814-62-9] | Non Selective (Phosphorylation substrates) | BCR-ABL | Inhibitor | Enzymes | Chronic myeloid leukaemia | CML | BCR-ABL1 fusion oncoprotein | Specifically Targeting the ABL Myristoyl Pocket